Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)
08/09/2026 13:10
BRIEF-Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae) Sept 8 (Reuters) - INTELLIA THERAPEUTICS, INC. NTLA.O:
INTELLIA THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW FOR LONVOGURAN ZICLUMERAN (LONVO-Z) FOR HEREDITARY ANGIOEDEMA (HAE)
INTELLIA THERAPEUTICS, - FDA ACCEPTS BLA FOR LONVO-Z AND GRANTS PRIORITY REVIEW WITH PDUFA DATE MARCH 10, 2027
INTELLIA THERAPEUTICS, - FDA NOT PLANNING TO HOLD ADVISORY COMMITTEE FOR LONVO-Z APPLICATION
Source text: ID:nGNX20NPCK
Further company coverage: NTLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)